StockNews.AI
UNCY
StockNews.AI
48 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

1. Pomerantz LLP is investigating possible securities fraud at Unicycive. 2. The FDA issued a Complete Response Letter for Unicycive's New Drug Application. 3. Unicycive's stock dropped nearly 30% following the FDA announcement. 4. Investors are urged to contact Pomerantz LLP regarding potential claims. 5. The investigation involves Unicycive's executives and their business practices.

5m saved
Insight
Article

FAQ

Why Bearish?

The sharp drop in stock price indicates investor concerns; historical examples show lasting negative impacts from FDA actions and lawsuits on similar biotech firms.

How important is it?

The investigations into securities fraud and FDA issues could severely impact investor confidence and stock price.

Why Short Term?

The immediate market reaction to the FDA's CRL and litigation announcement poses a high risk in the near future, as investor sentiment is sensitive to these events.

Related Companies

BLRXPTGXCRMD
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 30, 2025, Unicycive release issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis."  The press release stated that "[a]fter submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection."  On this news, Unicycive's stock price fell $2.03 per share, or 29.85%, to close at $4.77 per share on June 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News